• L J de Lloyd, S F Bell, T Roberts, J Freyer Martins Pereira, M Bray, T Kitchen, D James, P W Collins, and R E Collis.
• Department of Anaesthesia, University Hospital of Wales, Cardiff, United Kingdom. Electronic address: Lucy.delloyd@wales.nhs.uk.
• Int J Obstet Anesth. 2024 Aug 1; 59: 104209104209.

BackgroundViscoelastometric haemostatic assays (VHA) give rapid information on coagulation status, allowing individualised resuscitation.MethodsThis paper compares outcomes from two observational studies of postpartum haemorrhage (PPH) in the same institution, before and after practice changed from fixed ratio empirical transfusion of coagulation products with laboratory coagulation testing to VHA-guided fibrinogen replacement incorporated into an enhanced PPH care bundle. In both studies, all blood samples were taken near 1000 mL qualitative blood loss (QBL). In Study One, QBL started once PPH was identified, and resuscitation with coagulation blood products was empirical or based on laboratory tests of coagulation. In Study Two, QBL started at delivery and VHA was used to guide fibrinogen replacement if FIBTEM A5 was <12 mm (Claus fibrinogen ≤2 g/L) or to withhold coagulation products if FIBTEM A5 was >12 mm.ResultsImproved PPH outcomes were observed in Study Two, with rates of measured blood loss ≥2500 mL, ≥4 units red blood cell (RBC) transfusion, fresh frozen plasma transfusion and ≥8 units of any blood product transfusion all reduced (P < 0.01). Clinically significant improvements occurred in women with fibrinogen ≤2 g/L at study entry, where the proportion of women who received ≥4 units RBC transfusion fell from 67% in Study One to 0% in Study Two (P = 0.0007).ConclusionsThese results suggest that use of VHA as part of an early bundle of PPH care targeting fibrinogen ≤2 g/L with fibrinogen concentrate reduces PPH progression. The greatest benefit was seen when fibrinogen levels were ≤2 g/L at first testing.Crown Copyright © 2024. Published by Elsevier Ltd. All rights reserved.

20 keywords...

hide…